Dr. Rohit Dhall, MD
Neurology (Neurology Physician)
500 W Thomas Rd, Suite 300
Phoenix, AZ 85013
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 287
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 41581
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Arkansas Medical Sciences Little Rock, AR
Medical groups
- University of Arkansas for Medical Sciences (1,175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 287
- Services billed
- 435
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 162 | 139 |
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 60 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 63 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 29 | 18 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 29 | 14 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 21 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 19 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Phoenix, AZ | 293 |
| Rytary (carbidopa/levodopa) Other prescribers in Phoenix, AZ | 138 |
| Clonazepam Other prescribers in Phoenix, AZ | 113 |
| Donepezil Hcl Other prescribers in Phoenix, AZ | 90 |
| Zonisamide Other prescribers in Phoenix, AZ | 89 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Phoenix, AZ | 86 |
| Duloxetine Hcl Other prescribers in Phoenix, AZ | 67 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Phoenix, AZ | 62 |
| Amantadine (amantadine hcl) Other prescribers in Phoenix, AZ | 60 |
| Primidone Other prescribers in Phoenix, AZ | 57 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 10 payments worth $8,709 in total to this clinician.
| AbbVie Inc. | $6,949 |
|---|---|
| Mdd US Operations, LLC | $1,760 |
| Consulting Fee | $5,800 |
|---|---|
| Honoraria | $1,760 |
| Travel and Lodging | $797 |
| Food and Beverage | $352 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Mar 13, 2025 | Consulting Fee | $5,800 |
| Mdd US Operations, LLC Aug 6, 2025 | Honoraria | $1,760 |
| AbbVie Inc. Mar 7, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $588 |
| AbbVie Inc. Mar 6, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $181 |
| AbbVie Inc. Mar 13, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $28.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $65,951 in research payments for these studies, mostly to the institutions running them.
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT)
H. Lundbeck A S - A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Sage Therapeutics, LLC - A randomized, placebo-controlled, double-blind study to evaluate the effect of SAGE-718 on cognitive function in participants with huntington's disease
Sage Therapeutics, LLC - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985 - Open-label rollover study for continuing valbenazine administration for the treatment of chorea associated with huntington disease
Neurocrine Biosciences, Inc. - Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04201093 - Open-label Trial in Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04760769
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.